Skip to main content
Erschienen in:

01.05.2019 | ORIGINAL PAPER

Preparation and characterization of oxaliplatin drug delivery vehicle based on PEGylated half-generation PAMAM dendrimer

verfasst von: Dinh Tien Dung Nguyen, Long Giang Bach, Thi Hiep Nguyen, Minh Hieu Ho, Minh Nhat Ho, Dai Hai Nguyen, Cuu Khoa Nguyen, Thai Thanh Hoang Thi

Erschienen in: Journal of Polymer Research | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Dendrimers were well-known as a polymeric nanoparticle drug carrier system. Among them, polyamidoamine (PAMAM) dendrimers were firstly and systematically studied. Herein, to explore the additional modification of PAMAM for drug deliver application, this study assessed the PEGylated half-generation G3.5 to load oxaliplatin (OXA). The proton nuclear magnetic resonance (1H NMR) and Fourier-transform infrared spectroscopy (FTIR) spectroscopy were used to confirm the successful synthesis of G3.5, and PEGylated G3.5. PEG modification on G3.5 neutralized the negative charge of G3.5 that was confirmed by zeta potential measurement, and increased the dimension of G3.5 from 10 to 100 nm that was carried out by TEM technique. G3.5-PEG showed the high drug loading efficiency of 75.69%. The release kinetic of OXA from G3.5-PEG@OXA indicated that no burst released phenomenon occurred (11.95% within first hour) and sustainable release was achieved. In cytotoxicity test with normal cells of L929 fibroblasts, the carrier system of G3.5-PEG did not induced any cytotoxicity. To test the killing effect of G3.5-PEG@OXA on cancerous cells of human cervical cancer cells (HeLa), lung adenocarcinoma (A549), and breast cancer (MCF-7), resazurin test and live/dead staining assay was used to observe the alive cells. The increase of OXA amount in G3.5-PEG@OXA lead to decrease the cell viability from 79.90–56.97% (HeLa), 84.80–64.00% (A549), and 92.00–65.00% (MCF-7) after 48 h treatment.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Literatur
1.
Zurück zum Zitat David A (2017) Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Adv Drug Deliv Rev 119:120–142CrossRef David A (2017) Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Adv Drug Deliv Rev 119:120–142CrossRef
2.
Zurück zum Zitat Danhier F (2016) To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 244 (Pt A:108–121CrossRef Danhier F (2016) To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 244 (Pt A:108–121CrossRef
3.
Zurück zum Zitat Mintzer MA, Grinstaff MW (2011) Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 40(1):173–190CrossRef Mintzer MA, Grinstaff MW (2011) Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 40(1):173–190CrossRef
4.
Zurück zum Zitat Grabchev I, Staneva D, Vasileva-Tonkova E, Alexandrova R, Cangiotti M, Fattori A, Ottaviani MF (2017) Аntimicrobial and anticancer activity of new poly(propyleneamine) metallodendrimers. J Polym Res 24(11):210CrossRef Grabchev I, Staneva D, Vasileva-Tonkova E, Alexandrova R, Cangiotti M, Fattori A, Ottaviani MF (2017) Аntimicrobial and anticancer activity of new poly(propyleneamine) metallodendrimers. J Polym Res 24(11):210CrossRef
5.
Zurück zum Zitat Svenson S, Tomalia DA (2005) Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev 57(15):2106–2129CrossRef Svenson S, Tomalia DA (2005) Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev 57(15):2106–2129CrossRef
6.
Zurück zum Zitat D'Souza AA, Shegokar R (2016) Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv 13(9):1257–1275CrossRef D'Souza AA, Shegokar R (2016) Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv 13(9):1257–1275CrossRef
7.
Zurück zum Zitat Torchilin VP (1998) Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul 15(1):1–19CrossRef Torchilin VP (1998) Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul 15(1):1–19CrossRef
8.
Zurück zum Zitat Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB (2006) N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 17(1):179–188CrossRef Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB (2006) N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 17(1):179–188CrossRef
9.
Zurück zum Zitat Alcindor T, Beauger N (2011) Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 18(1):18–25CrossRef Alcindor T, Beauger N (2011) Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 18(1):18–25CrossRef
10.
Zurück zum Zitat Chen Y, Huang Z, Zhao H, Xu JF, Sun Z, Zhang X (2017) Supramolecular chemotherapy: cooperative enhancement of antitumor activity by combining controlled release of Oxaliplatin and consuming of Spermine by cucurbit[7]uril. ACS Appl Mater Interfaces 9(10):8602–8608CrossRef Chen Y, Huang Z, Zhao H, Xu JF, Sun Z, Zhang X (2017) Supramolecular chemotherapy: cooperative enhancement of antitumor activity by combining controlled release of Oxaliplatin and consuming of Spermine by cucurbit[7]uril. ACS Appl Mater Interfaces 9(10):8602–8608CrossRef
11.
Zurück zum Zitat Thanh VM, Nguyen TH, Tran TV, Ngoc UP, Ho MN, Nguyen TT, Chau YNT, Le VT, Tran NQ, Nguyen CK, Nguyen DH (2018) Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release. Mater Sci Eng C Mater Biol Appl 82:291–298CrossRef Thanh VM, Nguyen TH, Tran TV, Ngoc UP, Ho MN, Nguyen TT, Chau YNT, Le VT, Tran NQ, Nguyen CK, Nguyen DH (2018) Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release. Mater Sci Eng C Mater Biol Appl 82:291–298CrossRef
12.
Zurück zum Zitat Tummala S, Kumar MN, Pindiprolu SK (2016) Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles. Drug Deliv 23(9):3505–3519CrossRef Tummala S, Kumar MN, Pindiprolu SK (2016) Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles. Drug Deliv 23(9):3505–3519CrossRef
13.
Zurück zum Zitat Forbes LM, O’Mahony AM, Sattayasamitsathit S, Wang J, Cha JN (2011) Polymer end-group mediated synthesis of well-defined catalytically active platinum nanoparticles. J Mater Chem 21(39):15788CrossRef Forbes LM, O’Mahony AM, Sattayasamitsathit S, Wang J, Cha JN (2011) Polymer end-group mediated synthesis of well-defined catalytically active platinum nanoparticles. J Mater Chem 21(39):15788CrossRef
14.
Zurück zum Zitat Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, Pei Y (2010) Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 31(6):1360–1371CrossRef Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, Pei Y (2010) Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 31(6):1360–1371CrossRef
15.
Zurück zum Zitat Kaminskas LM, Boyd BJ, Porter CJ (2011) Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine 6(6):1063–1084CrossRef Kaminskas LM, Boyd BJ, Porter CJ (2011) Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine 6(6):1063–1084CrossRef
16.
Zurück zum Zitat Yavuz B, Pehlivan SB, Unlu N (2013) Dendrimeric systems and their applications in ocular drug delivery. Sci World J 2013:732340CrossRef Yavuz B, Pehlivan SB, Unlu N (2013) Dendrimeric systems and their applications in ocular drug delivery. Sci World J 2013:732340CrossRef
17.
Zurück zum Zitat Osada K, Christie RJ, Kataoka K (2009) Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery. J Royal Soc Interface 3:S325–S339 Osada K, Christie RJ, Kataoka K (2009) Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery. J Royal Soc Interface 3:S325–S339
18.
Zurück zum Zitat Sawant S, Shegokar R (2014) Cancer research and therapy: where are we today? IJCTO 2(4):020408 Sawant S, Shegokar R (2014) Cancer research and therapy: where are we today? IJCTO 2(4):020408
19.
Zurück zum Zitat Yellepeddi VK, Ghandehari H (2016) Poly(amido amine) dendrimers in oral delivery. Tissue Barriers 4(2):e1173773CrossRef Yellepeddi VK, Ghandehari H (2016) Poly(amido amine) dendrimers in oral delivery. Tissue Barriers 4(2):e1173773CrossRef
20.
Zurück zum Zitat Chen W, Tomalia DA, Thomas JL (2000) Unusual pH-dependent polarity changes in PAMAM dendrimers: evidence for pH-responsive conformational changes. Macromolecules 33(25):9169–9172CrossRef Chen W, Tomalia DA, Thomas JL (2000) Unusual pH-dependent polarity changes in PAMAM dendrimers: evidence for pH-responsive conformational changes. Macromolecules 33(25):9169–9172CrossRef
21.
Zurück zum Zitat Zhao Z, Lou S, Hu Y, Zhu J, Zhang C (2017) A Nano-in-Nano polymer-dendrimer nanoparticle-based Nanosystem for controlled multidrug delivery. Mol Pharm 14(8):2697–2710CrossRef Zhao Z, Lou S, Hu Y, Zhu J, Zhang C (2017) A Nano-in-Nano polymer-dendrimer nanoparticle-based Nanosystem for controlled multidrug delivery. Mol Pharm 14(8):2697–2710CrossRef
22.
Zurück zum Zitat Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE (2009) Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol 127(8):1043–1047CrossRef Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE (2009) Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol 127(8):1043–1047CrossRef
23.
Zurück zum Zitat Patil AS, Gadad AP, Hiremath RD, Joshi SD (2018) Biocompatible tumor micro-environment responsive CS-g-PNIPAAm co-polymeric nanoparticles for targeted Oxaliplatin delivery. J Polym Res 25(3):77CrossRef Patil AS, Gadad AP, Hiremath RD, Joshi SD (2018) Biocompatible tumor micro-environment responsive CS-g-PNIPAAm co-polymeric nanoparticles for targeted Oxaliplatin delivery. J Polym Res 25(3):77CrossRef
24.
Zurück zum Zitat William-Faltaos S, Rouillard D, Lechat P (2007) Cell cycle arrest by oxaliplatin on cancer cells. Fundam Clin Pharmacol 21(2):165–172CrossRef William-Faltaos S, Rouillard D, Lechat P (2007) Cell cycle arrest by oxaliplatin on cancer cells. Fundam Clin Pharmacol 21(2):165–172CrossRef
Metadaten
Titel
Preparation and characterization of oxaliplatin drug delivery vehicle based on PEGylated half-generation PAMAM dendrimer
verfasst von
Dinh Tien Dung Nguyen
Long Giang Bach
Thi Hiep Nguyen
Minh Hieu Ho
Minh Nhat Ho
Dai Hai Nguyen
Cuu Khoa Nguyen
Thai Thanh Hoang Thi
Publikationsdatum
01.05.2019
Verlag
Springer Netherlands
Erschienen in
Journal of Polymer Research / Ausgabe 5/2019
Print ISSN: 1022-9760
Elektronische ISSN: 1572-8935
DOI
https://doi.org/10.1007/s10965-019-1779-4

Weitere Artikel der Ausgabe 5/2019

Journal of Polymer Research 5/2019 Zur Ausgabe

    Marktübersichten

    Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.